Universität zu Köln

Sandherr, Michael, Hentrich, Marcus, von Lilienfeld-Toal, Marie, Massenkeil, Gero, Neumann, Silke, Penack, Olaf, Biehl, Lena and Cornely, Oliver A. (2015). Antiviral prophylaxis in patients with solid tumours and haematological malignancies-update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). Ann. Hematol., 94 (9). S. 1441 - 1451. NEW YORK: SPRINGER. ISSN 1432-0584

Full text not available from this repository.

Abstract

Reactivation of viral infections is common in patients with solid tumour or haematological malignancy. Incidence and severity depend on the extent of cellular immunosuppression. Antiviral prophylaxis may be effective to prevent viral reactivation. In 2006, the Infectious Diseases Working Party of German Society for Hematology and Medical Oncology (DGHO) published guidelines for antiviral prophylaxis in these patient populations. Here, we present an update of these guidelines for patients with solid and haematological malignancies undergoing antineoplastic treatment but not allogeneic stem cell transplantation. Relevant literature for reactivation of different viruses (herpes simplex virus (HSV), varicella zoster virus (VZV), hepatitis B virus (HBV) and respiratory viruses) is discussed to provide evidence-based recommendations for clinicians taking care of this patient population. We recommend a risk-adapted approach with (val)acyclovir against HSV and VZV in patients treated with alemtuzumab, bortezomib or purine analogues. Seasonal vaccination against influenza is recommended for all patients with solid or haematological malignancies regardless of antineoplastic therapy. Hepatitis B screening is recommended in lymphoproliferative disorders, acute leukaemia, and breast cancer, and during treatment with monoclonal anti-B-cell antibodies, anthracyclines, steroids and in autologous stem cell transplantation. In those with a history of hepatitis B prophylactic lamivudine, entecavir or nucleotide analogues as adefovir are recommended to prevent reactivation.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Sandherr, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Hentrich, Marcus UNSPECIFIED UNSPECIFIED UNSPECIFIED von Lilienfeld-Toal, Marie UNSPECIFIED UNSPECIFIED UNSPECIFIED Massenkeil, Gero UNSPECIFIED UNSPECIFIED UNSPECIFIED Neumann, Silke UNSPECIFIED UNSPECIFIED UNSPECIFIED Penack, Olaf UNSPECIFIED UNSPECIFIED UNSPECIFIED Biehl, Lena UNSPECIFIED UNSPECIFIED UNSPECIFIED Cornely, Oliver A. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-395918
DOI:	10.1007/s00277-015-2447-3
Journal or Publication Title:	Ann. Hematol.
Volume:	94
Number:	9
Page Range:	S. 1441 - 1451
Date:	2015
Publisher:	SPRINGER
Place of Publication:	NEW YORK
ISSN:	1432-0584
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language B-VIRUS REACTIVATION; CHRONIC LYMPHOCYTIC-LEUKEMIA; STEM-CELL TRANSPLANTATION; RECEIVING CYTOTOXIC CHEMOTHERAPY; BONE-MARROW-TRANSPLANTATION; BORTEZOMIB-TREATED PATIENTS; HERPES-SIMPLEX-VIRUS; CANCER-PATIENTS; HBV REACTIVATION; ACYCLOVIR PROPHYLAXIS Multiple languages Hematology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/39591